Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed

by Zacks Equity Research

Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.

Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News

by Zacks Equity Research

Pipeline and regulatory updates are the key highlights in the biotech sector this week.

Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal

by Zacks Equity Research

Regulatory news and licensing contracts are key highlights in the biotech sector this week.

Sweta Killa headshot

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Sweta Killa

Sector ETF report for PBE

Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids

by Zacks Equity Research

CHMP gives positive opinion to Vertex's (VRTX) label expansion of Orkambi.

Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Celldex (CLDX) reports narrower-than-expected loss in Q3. Revenues fall on reduced contract revenues and also miss estimates.

Spectrum (SPPI) Earnings and Sales Beat Estimates in Q3

by Zacks Equity Research

Spectrum (SPPI) reports narrower-than-expected loss in the third quarter and also beats on revenues. The company is on track to file a BLA for Rolontis by year end.

Perrigo (PRGO) Beats on Q3 Earnings, Cuts View, Shares Down

by Zacks Equity Research

Perrigo (PRGO) reports mixed third-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018 for the second straight quarter.

Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.

Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down

by Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) misses estimates for both earnings and sales in the third quarter. The company maintains its guidance for operating expenses.

VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y

by Zacks Equity Research

VIVUS (VVUS) reports narrower-than-expected loss in the third quarter. Sales increase year over year.

Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down

by Zacks Equity Research

Geron (GERN) beats earnings estimates in the third quarter but misses on revenues. Operating expenses decrease year over year.

The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals

Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal

by Zacks Equity Research

Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

Is a Beat in Store for CRISPR (CRSP) This Earnings Season?

by Zacks Equity Research

We expect CRISPR (CRSP) to provide updates on its pipeline candidates in the third quarter of 2018.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Vertex' (VRTX) Q3 gains on earnings and revenue beat with demand for its CF products rising high.

Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 9.00% and 0.20%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT

by Zacks Equity Research

Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.

Is a Beat in Store for Vertex (VRTX) This Earnings Season?

by Zacks Equity Research

On Vertex' (VRTX) third-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.

What's in Store for Anika Therapeutics (ANIK) in Q3 Earnings?

by Zacks Equity Research

Anika Therapeutics (ANIK) is scheduled to report third-quarter earnings on Oct 24.

Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?

by Zacks Equity Research

Bristol-Myers (BMY) is scheduled to report third-quarter earnings on Oct 25.

Vertex Pharmaceuticals (VRTX) Q3 Earnings Preview: What's Shaping Up?

by Zacks Equity Research

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CELG vs. VRTX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CELG vs. VRTX: Which Stock Is the Better Value Option?

J&J (JNJ) to Set the Ball Rolling for Pharma Q3 Earnings

by Zacks Equity Research

The positive trend seen in J&J's (JNJ) pharma segment sales is likely to continue in the third quarter.